MedTrace Logo

Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension

NCT00913094 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2009-06-11

No results posted yet for this study

Summary

To determine whether impedance cardiography (ICG) parameters can predict favorable or unfavorable blood pressure (BP) response and time to BP control prior to initiation or intensification of specific antihypertensive drug classes and drug combinations, independent of initial BP levels.

Conditions

Sponsors & Collaborators

  • CardioDynamics

    lead INDUSTRY

Principal Investigators

  • John M Flack, MD · Wayne State University, and Detroit Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-01-31
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00913094 on ClinicalTrials.gov